In the Harvesting Session the workshop moderators of the event will summarize the results of their discussions and highlight key findings from the World Cafés.
Senior Engineer Global Track & Trace, Merck Healthcare KGaA
Klaus Egner studied physics at the TU Darmstadt. After graduating with a degree in engineering, he trained technical business economist while working. Since 1998, Mr. Egner has been working for Merck KGaA, initially in the Automation department, where he was responsible for laboratories and in the field of chemistry. In 2004, his area of responsibility changed to the pharmaceuticals division with different areas of support (MES, production and packaging solids). In 2011, the implementation of Track & Trace in the packaging sector became step-by-step his main focus. Since Aug. 2019, he has been responsible for Track & Trace in packaging in a global function at Merck Healthcare KGaA.
The Pop in Your Job: I like digging deep into technical complexity to understand finally the full picture and making things operational. Learning about the interaction of technical and multi stakeholder based complexity provides an interesting extra layer for me.
Global Business Process Owner / Business System Owner Shopfloor Serialization, F. Hoffmann-La Roche AG
Global Business Process Owner / Business System Owner Shopfloor Serialization.
Global Serialization Expert, F. Hoffmann-La Roche
Global Serialization Expert
Project Manager Track&Trace, Bayer
Project Manager Track&Trace
Serialization Ops Lead, UCB Pharma SA
With over a decade of cross-functional experience in supply chain, compliance, and digital transformation, Marina brings deep expertise in serialization operations, labeling implementation, and data-driven project management. Known for leading international teams and driving continuous improvement initiatives, she specializes in aligning technology implementation with regulatory compliance and operational efficiency. Her work spans agile and traditional project environments, with a strong focus on stakeholder engagement, change management, and strategic process optimization across the pharmaceutical and FMCG industries.
Our pursuit is progress for people everywhere. That's why we take a closer look at things, ask questions and think ahead. We've been around for 350 years, yet our majority owners are still the descendants of Friedrich Jacob Merck, the man who founded our company in Darmstadt, Germany in 1668. Since then, we have become a truly global company, with 50,000 employees in 66 countries working on breakthrough solutions and technologies. In 2016, we invested a total of € 2.0 billion in research and development. We are Merck. The only exceptions are the United States and Canada. Here we operate as EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI).
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI).
Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population. At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses. Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish our communities around the world.
UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2024 Key Financials: € 6.15 billion global revenue Specialties: Neurology, Immunology
&nsbp;
